Bruce Walcheck advances cancer immunotherapy through translational NK cell research. Inventor on a non‑provisional patent for targeted ADAM17 blockers, combining cytokine modulation with protease checkpoint control to improve NK activation, expansion, and persistence for adoptive therapy.